CN111670032A - 预防或治疗阿尔茨海默氏病的方法 - Google Patents
预防或治疗阿尔茨海默氏病的方法 Download PDFInfo
- Publication number
- CN111670032A CN111670032A CN201980011347.7A CN201980011347A CN111670032A CN 111670032 A CN111670032 A CN 111670032A CN 201980011347 A CN201980011347 A CN 201980011347A CN 111670032 A CN111670032 A CN 111670032A
- Authority
- CN
- China
- Prior art keywords
- mice
- subject
- day
- app
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862624637P | 2018-01-31 | 2018-01-31 | |
| US62/624,637 | 2018-01-31 | ||
| PCT/US2019/016012 WO2019152627A1 (en) | 2018-01-31 | 2019-01-31 | Method for preventing or treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111670032A true CN111670032A (zh) | 2020-09-15 |
Family
ID=67478566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980011347.7A Pending CN111670032A (zh) | 2018-01-31 | 2019-01-31 | 预防或治疗阿尔茨海默氏病的方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11517554B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3746057B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7290872B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111670032A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3087865A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020007941A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019152627A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7229565B2 (ja) * | 2018-03-21 | 2023-02-28 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | メラノーマを治療するための方法 |
| EP4045009A4 (en) | 2019-10-14 | 2023-11-01 | Olatec Therapeutics LLC | METHOD FOR TREATING BREAST CANCER |
| EP4387729A4 (en) * | 2021-08-19 | 2025-07-09 | Olatec Therapeutics Inc | METHODS OF TREATMENT OF PARKINSON'S DISEASE |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120157524A1 (en) * | 2010-12-15 | 2012-06-21 | St Laurent Joseph | 3-methanesulfonylpropionitrile for treating inflammation and pain |
| WO2014066318A1 (en) * | 2012-10-25 | 2014-05-01 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2911547A1 (en) * | 2013-05-31 | 2014-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat alzheimer's disease |
| WO2015165961A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| ES2879678T3 (es) * | 2015-02-26 | 2021-11-22 | Univ Kentucky Res Found | Composiciones y procedimientos para el tratamiento de la degradación retiniana |
-
2019
- 2019-01-31 WO PCT/US2019/016012 patent/WO2019152627A1/en not_active Ceased
- 2019-01-31 CA CA3087865A patent/CA3087865A1/en active Pending
- 2019-01-31 JP JP2020541528A patent/JP7290872B2/ja active Active
- 2019-01-31 MX MX2020007941A patent/MX2020007941A/es unknown
- 2019-01-31 CN CN201980011347.7A patent/CN111670032A/zh active Pending
- 2019-01-31 EP EP19746676.6A patent/EP3746057B1/en active Active
-
2020
- 2020-07-29 US US16/942,312 patent/US11517554B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120157524A1 (en) * | 2010-12-15 | 2012-06-21 | St Laurent Joseph | 3-methanesulfonylpropionitrile for treating inflammation and pain |
| WO2014066318A1 (en) * | 2012-10-25 | 2014-05-01 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
Non-Patent Citations (3)
| Title |
|---|
| CARLO MARCHETTI ET AL: "OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation" * |
| DANIELS ET AL: "Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models" * |
| 钟欣等: "NLRP3炎症小体与阿尔茨海默病研究进展" * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7290872B2 (ja) | 2023-06-14 |
| US20200352897A1 (en) | 2020-11-12 |
| EP3746057B1 (en) | 2024-03-20 |
| MX2020007941A (es) | 2020-09-03 |
| US11517554B2 (en) | 2022-12-06 |
| CA3087865A1 (en) | 2019-08-08 |
| WO2019152627A1 (en) | 2019-08-08 |
| JP2021512086A (ja) | 2021-05-13 |
| EP3746057A1 (en) | 2020-12-09 |
| EP3746057A4 (en) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6837486B2 (ja) | 加齢に関連する認知障害及び神経炎症を予防及び/又は治療する方法 | |
| AU2005300727B2 (en) | Use of Pirlindole for the treatment of diseases which are characterized by proliferation of T-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis | |
| US20210283108A1 (en) | Method for treating neurodegenerative diseases | |
| US20040077591A1 (en) | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease | |
| US11517554B2 (en) | Method for preventing or treating Alzheimer's disease | |
| US20170151200A1 (en) | Prophylactic or therapeutic agent for idiopathic inflammatory myopathies | |
| US20180296632A1 (en) | Use of peptides to stimulate the immune system | |
| US20160310481A1 (en) | Laquinimod for treatment of cannabinoid receptor type 1(cb1) mediated disorders | |
| CN118593457B (zh) | 芬戈莫德在制备治疗缺血性脑卒中口鼻吸入制剂中的应用 | |
| US5693614A (en) | Drug for the treatment of senile dementia of the ischemic and hypoglycemic types | |
| EP3151827B1 (en) | Methods of treating chronic dry eye disease using c16:1n7 palmitoleate and derivatives thereof | |
| CN115624543B (zh) | 治疗偏头痛的药物、药物组合物、其制备方法和制药用途 | |
| US20210393549A1 (en) | New use of R-enantiomer of adrenergic beta 2 receptor agonists for treatment of inflammatory bowel disease and its extra intestinal manifestations | |
| US10548870B2 (en) | Method for treating multiple sclerosis | |
| Rubinow et al. | CSF somatostatin in affective illness and normal volunteers | |
| US11826340B1 (en) | Method for treateing or preventing ischemic optic neuropathy | |
| WO2022135462A1 (zh) | Magl抑制剂的医药用途 | |
| US20240269104A1 (en) | Method for treating parkinson's disease | |
| EP3072521A1 (en) | Use of recombined ganoderma lucidum immunoregulation protein (rlz-8) in preparing drugs for treating tissue fibrosis | |
| Evanti et al. | THE The efficacy of oral cyclosporine in a patient with drug reaction with eosinophilia and systemic symptoms probably due to cefadroxil | |
| US20250367203A1 (en) | Methods of treating epilepsy and reducing the incidence of seizures | |
| JP7607939B2 (ja) | 喘息を治療するための方法 | |
| US20220008402A1 (en) | Increased e-cadherin expression or activity for the treatment of inflammatory diseases | |
| CN117224519A (zh) | L-犬尿氨酸作为一种免疫调节剂在器官移植中的应用 | |
| US20160367503A1 (en) | Combination Medication for Neuro-Degenerative Diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Country or region after: U.S.A. Address after: USA New York Applicant after: Oratec Treatment Co. Address before: USA New York Applicant before: OLATEC INDUSTRIES LLC Country or region before: U.S.A. |